Shockwave Medical (SWAV) Stock Forecast, Price & News

9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Shockwave Medical in the last twelve months. There are currently 1 sell rating, 2 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" SWAV shares.
View SWAV analyst ratings or view top-rated stocks.

9 brokers have issued 1 year price objectives for Shockwave Medical's shares. Their SWAV share price forecasts range from $165.00 to $325.00. On average, they predict the company's stock price to reach $273.78 in the next twelve months. This suggests that the stock has a possible downside of 1.5%.
View analysts price targets for SWAV or view top-rated stocks among Wall Street analysts.

Shockwave Medical's stock was trading at $205.61 at the beginning of the year. Since then, SWAV shares have increased by 35.2% and is now trading at $277.89.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Monday, August 14th 2023.
View our SWAV earnings forecast.

Shockwave Medical, Inc. (NASDAQ:SWAV) issued its quarterly earnings data on Monday, May, 8th. The company reported $1.03 EPS for the quarter, topping the consensus estimate of $0.81 by $0.22. The company earned $161.10 million during the quarter, compared to analysts' expectations of $147.30 million. Shockwave Medical had a trailing twelve-month return on equity of 55.22% and a net margin of 43.18%. The business's revenue for the quarter was up 72.1% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.39 EPS.

ETFs with the largest weight of Shockwave Medical (NASDAQ:SWAV) stock in their portfolio include Janus Henderson Small/Mid Cap Growth Alpha ETF (JSMD), Northern Lights Fund Trust IV - Long Cramer Tracker ETF (LJIM), Neuberger Berman Disrupters ETF (NBDS), Invesco S&P MidCap 400 Pure Growth ETF (RFG), Invesco S&P MidCap Quality ETF (XMHQ), Pacer Lunt MidCap Multi-Factor Alternator ETF (PAMC), SPDR S&P Health Care Equipment ETF (XHE) and SoFi Next 500 ETF (SFYX).

Shockwave Medical updated its FY 2023 earnings guidance on Monday, May, 8th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $700.00 million-$720.00 million, compared to the consensus revenue estimate of $671.58 million.

8 employees have rated Shockwave Medical Chief Executive Officer Doug Godshall on Glassdoor.com. Doug Godshall has an approval rating of 89% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Shockwave Medical investors own include NVIDIA (NVDA), Walt Disney (DIS), Block (SQ), Trade Desk (TTD), Salesforce (CRM), Roku (ROKU), PayPal (PYPL), DexCom (DXCM), Alibaba Group (BABA) and Okta (OKTA).

(SWAV) raised $75 million in an initial public offering (IPO) on Thursday, March 7th 2019. The company issued 5,000,000 shares at $14.00-$16.00 per share. Morgan Stanley and BofA Merrill Lynch acted as the underwriters for the IPO and Wells Fargo Securities and Canaccord Genuity were co-managers.

Shockwave Medical trades on the NASDAQ under the ticker symbol "SWAV."

Shockwave Medical's stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (12.38%), FMR LLC (7.16%), Price T Rowe Associates Inc. MD (3.82%), JPMorgan Chase & Co. (3.48%), State Street Corp (3.30%) and Artisan Partners Limited Partnership (2.90%). Insiders that own company stock include Antoine Papiernik, Colin Cahill, Dan Puckett, Douglas Evan Godshall, Frank T Watkins, Frank T Watkins, Isaac Zacharias, Kurt F Gallo, Laura Francis, Maria Sainz, Sara Toyloy, Sofinnova Capital Vii Fcpr and Trinh Phung.
View institutional ownership trends.

Shares of SWAV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of SWAV stock can currently be purchased for approximately $277.89.

Shockwave Medical (NASDAQ:SWAV) has a market capitalization of $10.17 billion and generates $489.73 million in revenue each year. The company earns $216 million in net income (profit) each year or $6.34 on an earnings per share basis.

The company employs 1,001 workers across the globe.

Shockwave Medical's mailing address is 5403 Betsy Ross Drive, Santa Clara CA, 95054. The official website for the company is www.shockwavemedical.com. The company can be reached via phone at (877) 775-4846 or via email at investors@shockwavemedical.com.